Skip to content
Search

Latest Stories

Morningside Pharmaceuticals' Nik Kotecha named in top 50 most ambitious business leaders list

Dr Nik Kotecha, chairman of Morningside Pharmaceuticals, has been named in the LDC’s Top 50 Ambitious Business Leaders for 2021 list.

The list, which is supported by The Times, recognises and celebrates inspiring leaders from among the UK’s most successful and fast-growing businesses. Now in its fourth year, the 2021 programme was said to have received 600 nominations from across a diverse range of sectors.


Dr Kotecha’s Loughborough-based Morningside Pharmaceuticals was set up in the early 90s as a manufacturer and supplier of generic medicines to the UK and international export markets. Today, the company has over 240 generic and branded licenced medicines in the UK and EU, delivered twice daily to the NHS.

He is also chairman of the Randal Charitable Foundation which has contributed over £9m to significantly improve the lives of people in the UK and globally since it was established in 2017.

In his reaction to being included in a prestigious programme, Dr Kotecha said: “It is a great privilege and an honour to make this national list alongside so many talented business leaders and entrepreneurs.

"One of my passions is working with young entrepreneurs to help them develop the necessary skills and experience to create the success stories of tomorrow. I hope my story and experiences can inspire and encourage others to try new things and follow their entrepreneurial dreams.”

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less